Size, Share & Industry Analysis, By Cell Source (Autologous Engineered Macrophages, Allogeneic and Donor-Derived Macrophages, In Vivo Programmed Myeloid Cells), By Target Indication (Solid Tumor Oncology, Hematologic Malignancies, Autoimmune and Fibrotic Disorders), By Engineering Method (Ex Vivo Viral Engineering, Ex Vivo Nonviral Engineering, In Vivo RNA-LNP Programming), By Revenue Stream (Clinical Trial and Development Services, Licensing and Collaboration, Manufacturing and Cell-Processing Supply), and Regional Forecast, 2026-2034
Explore the report section by section.
The global CAR-M Cell Therapy Market was valued at USD 415.0 million in 2025 and is estimated at USD 437.2 million in 2026. The publisher-derived category is projected to reach USD 662.7 million by 2034, equivalent to a 5.3% CAGR over 2026–2034.
CAR-M Cell Therapy Market revenue includes engineered macrophage and monocyte therapeutics, in vivo RNA programming, modality-specific licensing, clinical development supply and related contract manufacturing. Unlike established CD19 CAR-T therapies, CAR-M products had no verified FDA-approved commercial franchise by October 2026. The publisher’s monetary series therefore represents a broad development-stage modality construct, not worldwide sales of approved CAR-M infusions. Unmodified macrophage immunotherapies, unrelated checkpoint inhibitors and conventional CAR-T products are excluded.
CREATE Medicines, formerly Myeloid Therapeutics, reported results in November 2025 from 27 patients receiving MT-302, an in vivo TROP2-targeting mRNA-LNP CAR therapy for solid tumors. The company described immune-cell programming within tumors, a manageable early safety profile and one confirmed partial response. The findings are preliminary and do not establish efficacy sufficient for marketing authorization. In April 2026 CREATE announced the first MT-304 patient treated in a HER2-directed program designed to engage both NK and myeloid cells.
Carisma Therapeutics provides an important counterexample to pipeline extrapolation. Its September 2025 SEC filing states that CT-0508 development ended in March 2024 and CT-0525 was discontinued in December 2024, with clinical activities ending in January 2025. Carisma’s March 2025 restructuring reduced staffing and initiated an orderly corporate wind-down, according to its SEC filing. Those discontinued candidates must not be counted as active commercial products, even though earlier CAR-M clinical studies remain relevant to the technology evidence base.
The modality faces difficult solid-tumor biology: tumor infiltration, macrophage polarization, antigen heterogeneity and durable expression must be addressed without unacceptable inflammation. Ex vivo manufacturing requires patient-specific cell collection and manipulation, while in vivo approaches use targeted RNA delivery to program immune cells directly. CREATE’s MT-302 and MT-303 clinical work, Liberate Bio’s targeted LNP platform and Chinese investigator-led studies provide distinct development routes. Their economic contribution comes from research, licensing and manufacturing contracts before any future approved therapy launch.
Source: CREATE MT-302; Carisma SEC filing; EMA ATMP framework.
The boundary covers CAR-engineered macrophage or monocyte modalities, including research-stage therapeutic programs and their directly attributable development transactions; ordinary CAR-T products and unrelated macrophage therapies are excluded.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Cell Source | Autologous Engineered Macrophages; Allogeneic and Donor-Derived Macrophages; In Vivo Programmed Myeloid Cells |
| By Target Indication | Solid Tumor Oncology; Hematologic Malignancies; Autoimmune and Fibrotic Disorders |
| By Engineering Method | Ex Vivo Viral Engineering; Ex Vivo Nonviral Engineering; In Vivo RNA-LNP Programming |
| By Revenue Stream | Clinical Trial and Development Services; Licensing and Collaboration; Manufacturing and Cell-Processing Supply |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Netherlands; United Kingdom; China; Australia; Japan; Brazil; Mexico; United Arab Emirates; South Africa |
| Key Market Players | CREATE Medicines, Inc.; Carisma Therapeutics, Inc. (legacy programs); Liberate Bio, Inc.; CellOrigin Biotechnology; Macera Therapeutics; Moderna, Inc.; MaxCyte, Inc.; WestGene Biopharma |
CAR-M refers to genetically engineered macrophages and monocytes expressing chimeric receptors designed to recognize tumor or disease-associated antigens. The definition includes autologous ex vivo cell products, donor-derived approaches and RNA-LNP therapies that program myeloid cells inside the patient. In vivo candidates with combined NK and myeloid activity are included only for the documented macrophage-directed component; pure CAR-T and CAR-NK therapies remain outside the market.
No CAR-M product was verified as commercially approved in the FDA or EMA product records. The USD 415.0 million 2025 figure is a publisher-derived estimate of development, licensing, collaboration, clinical trial supply and manufacturing activity, not an audited sum of CAR-M therapy sales. Discontinued Carisma assets remain historical comparators and should not be counted as current clinical supply. Partner licensing and contract manufacturing payments are recognized once, not duplicated across recipient and sponsor.
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| In vivo myeloid programming and RNA-LNP delivery | High | +2.50% | High | High | High |
| Solid tumor treatment demand and antigen targeting | High | +1.90% | High | High | High |
| Clinical proof-of-mechanism in MT-302 patients | Medium-High | +1.30% | High | Medium | Medium |
| Combination studies in frontline oncology | Medium | +1.10% | Medium | High | High |
| Specialized cell processing and licensing contracts | Low-Medium | +0.70% | Medium | Medium | Medium |
| Others (biomarkers, new cell sources, academic collaborations) | Low | +0.30% | Low | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|---|---|---|---|---|
| High clinical attrition and discontinued programs | High | -1.20% | High | High | Medium |
| Tumor heterogeneity and inflammatory toxicity | Medium-High | -0.80% | High | High | High |
| Expensive GMP release and patient-specific manufacturing | Medium | -0.40% | High | Medium | Medium |
| Others (trial recruitment, reimbursement, scale-up) | Low | -0.10% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 5.3% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
CAR-T success in hematologic malignancies has not translated directly into reliable control of most solid tumors. Macrophages can enter tumor tissue, phagocytose targets and influence antigen presentation, giving CAR-M developers a different immune-cell mechanism. CREATE’s MT-302 trial uses a TROP2-targeted receptor delivered through mRNA-LNPs, and its November 2025 report described tumor infiltration by programmed myeloid cells. Early mechanistic activity supports clinical investment, but larger trials must demonstrate durable responses and acceptable safety before commercialization. Variable HER2, TROP2 and GPC3 expression across solid tumors remains a development risk for antigen-directed macrophage products.
Autologous CAR-M production requires collecting patient cells, engineering them and releasing a batch before infusion. CREATE’s MT-302 and MT-303 use systemic mRNA-LNP dosing to program myeloid cells inside the body, avoiding some individualized manufacturing steps. In April 2026 CREATE dosed its first MT-304 patient in a HER2-targeted multi-immune study. The approach could lower logistics costs if repeat dosing proves safe and clinically useful. Targeted delivery remains difficult because off-target uptake and inflammatory activation can narrow the therapeutic window.
CREATE reported 27 MT-302-treated patients in November 2025, including one confirmed partial response and intratumoral CAR-positive myeloid cells. The company also reported a high-grade neurotoxicity event at the highest tested dose and low-grade cytokine release syndrome in some participants. These observations support dose optimization rather than claims of established efficacy. Investigators must monitor neurotoxicity, cytokine effects and persistence in combination regimens. Regulatory approvals will require controlled evidence that distinguishes a true treatment benefit from early biomarker changes.
Carisma’s SEC filings document the discontinuation of CT-0508 and CT-0525 during 2024, followed by the end of associated clinical activity in January 2025. The company’s March 2025 workforce reduction and planned wind-down reduced the number of active U.S. CAR-M developers. Such closures increase the importance of diversified clinical programs and licensing agreements for surviving technology holders. Early-stage financing must cover vector manufacturing, safety monitoring and multiple dose cohorts before any therapy revenue is available. Historical program spending is not evidence of current marketable products.
The EMA advanced-therapy framework treats substantially manipulated cell therapies and gene-modified products as regulated medicinal products. Its investigational ATMP guideline took effect in July 2025 and specifies quality, nonclinical and clinical documentation expectations. For CAR-M, sponsors need potency assays, identity and purity testing, consistent engineering and controlled release specifications. In vivo RNA products face additional questions about biodistribution and transient receptor expression. Compliance costs can create contracted laboratory and manufacturing revenue but delay first product approvals if clinical or analytical packages remain incomplete.
Sources: CREATE Medicines 2025–2026; Carisma 2025 SEC 10-Q; EMA ATMP guidance; ClinicalTrials.gov records.
CREATE announced positive first-in-human MT-302 observations in November 2025 and began frontline MT-303 dosing in December 2025. The two programs target TROP2-expressing solid tumors and GPC3-positive liver cancer respectively. In April 2026 the company dosed the first patient with MT-304, designed to activate NK and myeloid cells against HER2-positive cancers. These events broaden the clinical dataset while remaining early-phase studies. The principal commercial question is whether repeated in vivo dosing can produce durable responses with manageable adverse effects.
Amsterdam UMC began treating patients in October 2025 in a trial combining MT-302 with standard gastroesophageal cancer regimens. CREATE described this as a frontline study, contrasting with earlier heavily pretreated cohorts. Combination treatment may improve immune activation but also complicates attribution of adverse events and response. The EU advanced-therapy rules require clinical evidence and manufacturing controls appropriate to the investigational product. European site participation provides research revenue opportunities, not evidence of an authorized CAR-M treatment.
ClinicalTrials.gov identifies an HER2-targeted macrophage study for advanced gastric cancer with peritoneal metastases, with Macera Therapeutics named as collaborator. CellOrigin separately reported initial SY001 dosing in China during 2023. Such investigator-led research extends macrophage engineering into different solid-tumor settings and may inform local manufacturing methods. The programs remain investigational; their registration or early dosing does not establish commercial reimbursement, proven efficacy or product approval by Chinese regulators. Manufacturing controls and independently reviewed clinical outcomes remain necessary before any marketed supply.
Liberate Bio reported a 2026 license to CAR receptor intellectual property originating with Carisma and the University of Pennsylvania. Its RAPTOR platform focuses on delivery to myeloid and other difficult-to-target cells using lipid nanoparticles. Licensing can preserve value from prior research even when a developer winds down operations. However, a license agreement is not proof that the underlying clinical product remains active or that an engineered macrophage therapy has received regulatory authorization. Contract milestones and licensing scope determine which organization recognizes revenue.
CREATE’s MT-304 was designed to program NK and myeloid cells through a HER2-directed receptor, while separate programs target T cells or myeloid cells. A combined immune-cell therapy must allocate revenue to the macrophage-directed component rather than count the entire CAR-T or CAR-NK franchise. This matters for manufacturers supplying lipid nanoparticles, cell processing and trial materials. Clinical investigators will need cell-specific biomarkers to demonstrate which population mediates tumor responses and safety findings. Targeted delivery must also be assessed for off-target uptake in healthy tissues.
The Cell Source segmentation distinguishes autologous engineered macrophages, donor-derived products and myeloid cells programmed directly in vivo. Each clinical program is assigned according to its principal cell origin or programming approach. The framework excludes unmodified tumor-associated macrophages and conventional CAR-T infusions.
Autologous Engineered Macrophages represented an estimated ~58% of 2025 revenue. Carisma’s historical CT-0508 and CT-0525 programs used patient-derived myeloid cells, while early investigator-led studies also explored autologous collection and engineering. Individualized processing generates cell isolation, viral or nonviral engineering and quality-control demand. Carisma’s discontinued programs remain historical evidence, not ongoing product supply.
Donor-derived and standardized cell sources could improve batch scale and reduce patient-specific logistics. However, immune compatibility, persistence and manufacturing reproducibility require direct clinical evaluation. Companies developing off-the-shelf approaches must demonstrate that macrophage identity and function remain consistent after cryopreservation and transport.
CREATE’s MT-302 and MT-303 encode CAR constructs in RNA-LNP formulations delivered systemically. This avoids separate collection of a patient’s macrophages, but shifts development risk toward selective tissue delivery and control of receptor expression. Liberate Bio also targets myeloid-cell programming with specialized lipid nanoparticles.
Autologous programs retain a large historical development base, while in vivo myeloid programming may capture more future clinical activity if early trial findings are reproduced. The revenue boundary assigns platform licenses and cell-manufacturing fees to the actual transaction, not the same patient twice.
Target Indication separates oncology applications in solid tumors, blood cancers and non-oncology immune disorders. Solid tumors dominate current CAR-M research because macrophages can infiltrate tissues and influence the tumor microenvironment. Sponsor trial protocols and disease-specific inclusion criteria determine how development service revenue is allocated among indications.
Solid Tumor Oncology represented an estimated ~87% of 2025 revenue. CREATE’s TROP2 MT-302, GPC3 MT-303 and HER2 MT-304 programs focus on solid tumors. Earlier Carisma HER2 studies and Chinese investigator-led macrophage trials also belong here, although some have ended. Antigen heterogeneity and immune suppression remain major barriers to durable clinical response.
Engineered monocyte research has explored CD5-expressing T-cell malignancies, but macrophage products remain far less established than approved CD19 CAR-T medicines. The latter are excluded because their active cells and mechanisms differ. Early trials must establish safe myeloid activity in blood and marrow compartments.
Myeloid cells participate in tissue inflammation and fibrosis, motivating research beyond cancer. Carisma previously discussed macrophage engineering for fibrosis, and Liberate Bio describes programs targeting immune cells relevant to autoimmune disease. These initiatives remain development-stage and cannot be described as approved treatments for lupus or fibrotic disease.
Solid tumors should remain the leading research application through 2034, but clinical attrition can change which antigens attract financing. Hematology and autoimmune programs are potential extensions rather than established commercial revenue streams.
Engineering Method separates viral ex vivo modification, nonviral ex vivo techniques and in vivo RNA-LNP delivery. These methods differ in manufacturing controls, expression duration and patient logistics, and therefore create distinct supplier revenue streams.
Historical CAR-M programs used viral vectors to introduce engineered receptors into patient-derived macrophages. This approach requires specialized transduction, release testing and batch traceability. Carisma’s CT-0508 development ended in 2024, so its technical history should not be mistaken for an active commercial program.
MaxCyte’s CARMA history and electroporation technology illustrate nonviral approaches for engineering immune cells. Nonviral methods can simplify vector supply but still require demonstration of expression, viability and reproducible manufacturing. Their contribution to CAR-M is restricted to macrophage-specific projects rather than all cell therapy platform revenue.
CREATE’s MT-302 and MT-303 clinical programs deliver mRNA encoding CAR receptors into myeloid cells inside the body. This reduces individualized cell handling but demands control of biodistribution, repeat-dose safety and receptor expression. The 2025 MT-302 clinical update described programmed cells within tumor tissue.
In vivo programming is the principal new platform direction, while ex vivo methods retain a role where cell identity and release attributes can be tightly controlled. Manufacturing and licensing income should be mapped to the engineering method used by each specific candidate.
Revenue Stream assigns clinical development services, licensing and collaboration payments, and manufacturing or processing supply to separate buckets. No approved CAR-M therapy sales are assumed in the 2025 base. This classification prevents pipeline valuations or broad company research spending from being treated as patient infusion receipts.
Clinical studies such as MT-302 and MT-303 require investigational supply, monitoring, biomarker assays and protocol-specific production. Payments for these services can occur before approval, but clinical trial budgets are not themselves evidence of commercial patient demand. CREATE’s reported trial cohorts provide context for the development phase.
Liberate Bio’s 2026 license to myeloid CAR intellectual property illustrates how technology rights can create transactions without a marketed therapy. The contractual milestones and payment dates in a myeloid receptor licensing agreement determine when associated revenue is recognized. Former Carisma programs cannot be counted as ongoing treatment sales merely because related patents are licensed.
Cell processing, RNA-LNP formulation and vector manufacturing generate project-specific supply contracts. MaxCyte and other platform suppliers can serve cell engineering research, but company-wide instrument sales cannot be assigned to CAR-M without contract evidence. Manufacturing fees should not be duplicated in a sponsor’s gross development receipts.
Development-service income is sensitive to trial enrollment and sponsor financing. Licensing may rise when new intellectual property is adopted, while manufacturing contracts depend on whether clinical programs advance to larger dose cohorts and eventual commercial production.
CAR-M research is geographically concentrated in U.S., European and Chinese development networks. Modeled regional revenue reflects research and contracted supply rather than approved macrophage-cell treatment purchases.
North America represented an estimated ~46% of 2025 CAR-M modality value, reflecting a concentration of U.S. biotechnology developers, trial sponsors and cell-engineering suppliers. CREATE Medicines conducts in vivo CAR programs and has reported human MT-302 data, while Liberate Bio develops myeloid-targeted lipid nanoparticle delivery. MaxCyte’s historic CARMA research and electroporation technology provide a separate example of nonviral cell engineering. Carisma’s 2025 SEC filings are essential when evaluating the regional pipeline: the company stopped CT-0508 and CT-0525 and moved toward a wind-down, so those programs are not active U.S. commercial assets. Regulatory oversight by the FDA requires investigational applications, product identity testing and clinical safety data. The absence of an approved CAR-M therapy means modeled regional value is dominated by development, licensing and contract work. U.S. clinical activity can still support research vendors without implying reimbursed CAR-M infusions.
CREATE reported results from 27 MT-302-treated patients in November 2025, including evidence of programmed myeloid cells in tumor biopsies. Carisma’s September 2025 SEC filing separately confirmed the end of its legacy clinical programs and a workforce reduction. Together, these records show why active trial status must be checked company by company. No FDA-approved CAR-M product was identified in the agency’s cellular and gene therapy listings.
Source: CREATE Medicines.
Canadian research institutions can contribute oncology trial infrastructure and immune-cell engineering expertise, but no Canadian CAR-M product authorization was established from the reviewed primary sources. U.S. trial findings should not be treated as evidence of Canadian commercial access. The principal opportunity lies in cross-border development partnerships, GMP process transfer and future clinical participation after appropriate national authorization. Patient infusion sales are excluded until a product receives approval.
Source: FDA.
Europe hosts translational research and clinical evaluation of engineered myeloid therapies, with an important example at Amsterdam UMC. In October 2025 CREATE announced the first patient dosed in the SPaCE-MT trial combining MT-302 with standard therapy for advanced gastroesophageal cancer. This moves the technology into a frontline combination setting while remaining investigational. The EMA classifies substantially manipulated cell therapies and gene-modified products under its advanced therapy framework. Updated investigational ATMP guidance became effective in July 2025, setting expectations for quality, nonclinical and clinical evidence. European clinical sites may generate trial-service demand and collaborate on formulation, cell processing and biomarker development. They cannot market a CAR-M product without the necessary authorization. European regional estimates should therefore emphasize clinical supply, sponsored research and licensing rather than routine hospital reimbursement. Cross-border trial operations also face different hospital contracting and patient recruitment requirements.
Amsterdam UMC began dosing in the SPaCE-MT frontline study in October 2025, according to CREATE. The trial evaluates MT-302 with capecitabine and oxaliplatin, with additional immunotherapy options in advanced gastroesophageal cancer. Such combinations may test whether myeloid reprogramming improves response to standard care. They remain clinical investigations and do not establish an approved Dutch CAR-M medicine or reimbursed treatment pathway.
Source: CREATE Medicines.
UK cell and gene therapy developers operate under advanced therapy regulatory standards comparable in purpose to EMA quality requirements. CAR-M manufacturing would require cell identity, potency, release and safety controls before patient dosing in authorized trials. Published U.S. and Dutch results can guide protocol design but cannot replace local approvals. Commercial revenue remains contingent on clinical success, manufacturing scalability and future payer evaluation.
Source: EMA.
Asia-Pacific includes Chinese investigator-led macrophage studies and Australian participation in international in vivo CAR research. ClinicalTrials.gov identifies a HER2-directed CAR-macrophage study for gastric cancer with peritoneal metastases involving Macera Therapeutics. CellOrigin reported first SY001 patient dosing in China during 2023, supporting the region’s early experimental activity. In Australia, the Kinghorn Cancer Centre participated in the MT-302 first-in-human work reported by CREATE in November 2025. Chinese developers may use local manufacturing and investigator-sponsored pathways to test different cell sources and antigens, but trial registration does not establish national marketing approval. Japan and South Korea have advanced cell therapy regulation and manufacturing infrastructure, yet no approved CAR-M product was verified there. The regional forecast therefore relies on clinical partnerships, specialized supply and technology licensing. Manufacturing feasibility and safety evidence will determine whether any of these programs progress beyond small cohorts.
A ClinicalTrials.gov study describes autologous HER2-targeted macrophages for advanced gastric cancer with peritoneal metastases and lists Macera Therapeutics as a collaborator. CellOrigin separately announced SY001 first-patient dosing in 2023. The Macera and CellOrigin examples document investigational research rather than authorized commercial macrophage-cell treatments in China. Future market entry depends on clinical outcomes, standardized production and authorization by the appropriate Chinese regulator.
Source: ClinicalTrials.gov.
CREATE’s November 2025 MT-302 announcement quoted investigators at the Kinghorn Cancer Centre in Sydney and described 27 treated patients. The Australian research contribution centers on trial recruitment, immune monitoring and clinical interpretation rather than an approved CAR-M product. Expansion into frontline regimens requires further safety and efficacy evaluation, including assessment of adverse events when combined with standard anticancer medicines.
Source: CREATE Medicines.
Latin America remains an early research and technology-transfer opportunity rather than an established market for reimbursed CAR-M infusions. Brazil and Mexico have oncology centers and biopharmaceutical research capabilities, but the reviewed official sources did not establish a locally approved CAR-macrophage therapy. Potential participation would begin with authorized clinical trials, manufacturing partnerships and biomarker laboratory services. The cost of patient-specific cell processing may be especially challenging where specialist facilities are concentrated in major cities. In vivo RNA programming could eventually reduce some logistics if clinical safety and efficacy are demonstrated, but that benefit has not been established as a commercial treatment outcome. Regional revenue allocations should therefore be understood as modeled research, licensing and supply activity. Public health purchasers are unlikely to fund routine CAR-M care before regulators confirm an acceptable benefit-risk profile. National differences in advanced therapy oversight will also affect how quickly trial sponsors can establish local study sites.
Brazilian oncology research centers could participate in multicenter CAR-M studies once national ethics and regulatory permissions are obtained. The EMA’s advanced therapy guidance provides a useful technical reference for quality and trial documentation, not a Brazilian authorization. No approved CAR-M medicine or routine public reimbursement was verified in the reviewed primary records. Early contracts would relate to clinical research and manufacturing services rather than commercial patient infusions.
Source: EMA.
Mexico’s oncology institutions may evaluate macrophage-directed therapies through investigator partnerships, but international MT-302 data cannot be extrapolated into a Mexican licensed product. Any clinical import or local manufacturing arrangement would need the relevant regulatory authorization and quality controls. The principal near-term economic activity would be protocol execution, testing and clinical supply. CAR-M patient access in Mexico would remain restricted to an authorized clinical investigation until local product approval.
Source: ClinicalTrials.gov.
Middle East and African opportunities are concentrated in specialist oncology research and future international trial participation. Advanced hospitals in Gulf countries can support cell therapy research, but CAR-M remains investigational and requires a distinct clinical and regulatory pathway from approved CAR-T treatments. In much of Africa, specialized GMP facilities, cell-processing capacity and oncology trial infrastructure are limited relative to the complexity of autologous engineered macrophage production. In vivo RNA programming could change manufacturing logistics if repeat dosing and cell targeting are validated in larger studies. For now, modeled value is associated with potential collaborations, laboratory services and technology transfer rather than a verified regional product franchise. The EMA warns that advanced therapies offered outside authorized clinical trials or without clear product approval may be unregulated. That distinction matters when assessing claims from private treatment providers. Country-specific clinical approvals and contract evidence are needed before assigning realized revenue to the region.
UAE specialist oncology centers could collaborate on early cell therapy trials, but no local CAR-M authorization was verified from the reviewed official records. Any investigational macrophage treatment would require an approved protocol, GMP supply and patient safety monitoring. EMA guidance warns against interpreting an experimental therapy offered outside a regulated study as an authorized medicine. Forecast activity therefore centers on research partnerships rather than established commercial doses.
Source: EMA.
South African clinical institutions may contribute translational oncology research, but autologous CAR-M programs require specialized cell collection, engineering and release testing. The published CREATE and Carisma histories illustrate that even advanced U.S. programs can be delayed or discontinued. No South African marketed CAR-M product was identified in the primary evidence. Local demand cannot be quantified from general cancer incidence without a licensed therapy and purchasing pathway.
Source: Carisma SEC.
The CAR-M competitive field consists of development-stage ex vivo cell engineering and in vivo RNA programming approaches. CREATE is advancing active in vivo CAR programs, while Carisma’s historic ex vivo work ended and its assets entered a wind-down process. Chinese investigator-led products, myeloid-targeted lipid nanoparticles and specialist cell-engineering platforms add different sources of potential value.
MT-302 and MT-303 are clinical RNA-LNP programs; MT-304 entered patient dosing in April 2026. The company reports human immune-programming evidence but has no marketed CAR-M product.
CT-0508 and CT-0525 development stopped during 2024. The company’s 2025 SEC filing states it no longer intends to resume its historical research activity and is pursuing a wind-down.
Liberate licenses myeloid CAR designs and develops targeted LNPs; WestGene entered a 2026 collaboration with CREATE. These are platform and research relationships, not licensed patient therapies.
CellOrigin reported early SY001 dosing, Macera is named on a Chinese HER2 CAR-M study, and MaxCyte has historical CARMA and nonviral engineering capabilities. Clinical development status differs between CellOrigin’s SY001, Macera’s investigator-linked research and MaxCyte’s terminated historical trial.
CREATE’s clinical strategy seeks to program macrophages directly in vivo rather than rely exclusively on patient-specific cell manufacturing. Its November 2025 MT-302 report described a measurable tumor-microenvironment effect in a small patient cohort, while December 2025 MT-303 and April 2026 MT-304 milestones expanded the program portfolio. Larger controlled trials are still needed before efficacy claims can support an approval application. For CREATE’s investigational MT-302 and MT-303 programs, clinical trial services and manufacturing contracts provide near-term economic activity.
Carisma’s withdrawal illustrates the financial and clinical risk of early macrophage cell therapy. The company discontinued CT-0508 and CT-0525 and then reduced staff during 2025, despite having contributed important initial CAR-M human research. Legacy patents and data may retain licensing value, but the underlying therapies cannot be counted as active clinical supply. Liberate’s 2026 myeloid receptor license provides a possible path for intellectual property reuse under a different development platform.
CellOrigin and Macera represent Chinese research routes, whereas MaxCyte’s nonviral engineering platform provides enabling technology with broader cell therapy applications. Revenue allocation requires molecule-specific attribution; a supplier’s total electroporation, LNP or cell-processing sales cannot be counted as CAR-M. The competitive outlook is therefore sensitive to clinical trial continuation, safety findings and the ability to establish reproducible GMP manufacturing.
August 2026: CREATE Medicines announced a collaboration with WestGene Biopharma on targeted LNP technology and in vivo CAR programs, including dual-target and solid-tumor projects. The agreement adds delivery and development capabilities but does not constitute authorization of a CAR-M medicine. Its commercial value depends on later clinical milestones and program-specific licensing terms. Source
April 2026: CREATE reported the first MT-304 patient dosed in a Phase I/II study targeting HER2-positive solid tumors. The construct is designed to engage NK and myeloid cells through in vivo RNA programming. The event expands clinical evaluation beyond the earlier TROP2 and GPC3 programs, while remaining investigational. Source
December 2025: CREATE announced first-patient dosing in a frontline MT-303 hepatocellular carcinoma combination study with atezolizumab and bevacizumab. The GPC3-targeted RNA-LNP program tests whether myeloid programming can be integrated with standard systemic therapy. Results will need to separate the experimental component’s effects from established treatment. Investigators must document adverse events and response duration across successive dose cohorts. Source
November 2025: CREATE presented MT-302 first-in-human findings from 27 patients with advanced solid tumors. It reported intratumoral programmed myeloid cells, one confirmed partial response and dose-dependent safety findings. The small early cohort supports further investigation but cannot establish efficacy sufficient for commercial approval. Additional trial cohorts must examine response durability and dose-dependent adverse events. Source
October 2025: Amsterdam UMC began dosing patients in the SPaCE-MT frontline study combining MT-302 with gastroesophageal cancer standard therapy. The study evaluates an in vivo CAR approach earlier in treatment than initial heavily pretreated cohorts. European trial participation creates clinical research activity without creating an authorized product. Source
March 2025: Carisma approved a cash-preservation plan and reduced its workforce after stopping CT-0508 and CT-0525 development in 2024. Its September 2025 SEC report says the company no longer intends to resume historical research and is pursuing an orderly wind-down. The disclosure materially changes how legacy CAR-M programs should be represented in competitive analyses. Source
The publisher-derived CAR-M category is projected to reach USD 662.7 million in 2034 from USD 437.2 million in 2026, representing 5.3% CAGR. The forecast concerns investigational development, licensing and specialist supply, not an established global market in approved CAR-macrophage infusions.
| Forecast Factor | 2025–2026 Evidence | Effect Through 2034 |
|---|---|---|
| In vivo RNA programs | MT-302, MT-303, MT-304 | Potential clinical pipeline expansion |
| Clinical risk | Carisma stopped two lead candidates | High program attrition risk |
| Solid tumor combinations | Amsterdam UMC and frontline HCC trials | More complex efficacy testing |
| Cell engineering | Ex vivo and targeted LNP approaches | Different manufacturing cost structures |
| Regulatory quality | EMA ATMP guideline effective 2025 | Higher GMP and evidence requirements |
| IP and collaboration | Myeloid receptor licenses and LNP partnerships | Milestone-linked development receipts |
In vivo programming is likely to receive substantial development attention because it avoids collecting and engineering each patient’s macrophages outside the body. CREATE’s MT-302 and MT-303 use RNA-LNP constructs to direct myeloid cells, while MT-304 extends programming to NK and myeloid populations. These approaches still require controlled evaluation of delivery specificity, adverse events and durable clinical benefit. The early MT-302 response observations do not establish FDA authorization or receipts from marketed CAR-M therapy.
Carisma’s 2024 program discontinuations demonstrate the risk that a CAR-M clinical pathway may end before approval. Carisma’s 2024 shutdown of CT-0508 and CT-0525 demonstrates that positive feasibility findings do not guarantee sustained funding or eventual authorization. Carisma’s March 2025 workforce reductions illustrate how sponsor restructuring can terminate contracted research and clinical supply. Intellectual property licenses can preserve some value, but the forecast must not treat stopped trials as active patient-treatment supply.
Europe and Asia-Pacific can contribute trial sites and manufacturing partners as investigational studies expand. Amsterdam UMC’s MT-302 frontline study and Chinese HER2 macrophage trials provide concrete examples of geographic participation. Regulatory quality standards for cell engineering, RNA formulation and clinical safety will influence cost and trial duration. Country-level revenue may therefore be uneven and concentrated in a small number of research networks.
Potential upside comes from convincing controlled evidence in solid tumors, reliable targeted delivery and combination regimens that demonstrate a clinically meaningful improvement over standard therapy. Downside risks include tumor heterogeneity, inflammatory toxicity, expensive GMP production and financing constraints. Until a regulator approves a CAR-M medicine, market values should be presented as modality development estimates and verified contract revenue rather than routine reimbursed treatment sales.
Coverage addresses engineered macrophage and monocyte technologies, clinical evidence, development contracts, cell-processing suppliers and regulatory status across five regions.
The publisher-defined CAR-M modality value is USD 415.0 million for 2025. It covers research, licensing, clinical supply and manufacturing activities rather than sales of an approved macrophage cell therapy. No FDA-authorized CAR-M product was verified in the reviewed records, so the headline should not be compared directly with marketed CAR-T treatment revenue.
The forecast reaches USD 662.7 million in 2034, up from USD 437.2 million in 2026. The normalized compound growth rate is 5.3% during 2026–2034. Clinical progress, research financing and the development of scalable RNA delivery determine whether this publisher-derived modality trajectory is achieved.
No FDA-approved CAR-macrophage product was identified in the reviewed cellular and gene therapy listings. CREATE’s MT-302, MT-303 and MT-304 remain investigational programs, while Carisma discontinued CT-0508 and CT-0525. Early clinical dosing and biomarker changes should not be described as commercial approval or proven clinical efficacy.
CAR-M engineers macrophages or monocytes to recognize targets and modify innate immune activity, while CAR-T engineers T lymphocytes. Engineered macrophages may engulf target cells and alter antigen presentation, unlike CAR-T cells that primarily rely on T-cell cytotoxicity. The two modalities have different manufacturing, persistence and safety questions, so approved CAR-T sales are excluded from CAR-M market revenue.
North America accounts for an estimated 46% of 2025 modality-related value. U.S. developers, clinical research infrastructure and specialist cell-engineering suppliers support that allocation. It does not represent audited sales of approved CAR-M infusions, because no marketed product was identified in the reviewed FDA records.
Carisma stopped CT-0508 development in March 2024 and CT-0525 in December 2024, with related clinical activities ending in January 2025. Its September 2025 SEC filing described workforce reductions and an orderly wind-down. Historical studies remain informative, but the discontinued candidates should not be counted as active commercial treatments.
MT-302 is an investigational in vivo CAR therapy that uses mRNA-LNPs to program myeloid cells against TROP2-positive solid tumors. CREATE reported observations from 27 treated patients in November 2025, including programmed immune cells in tumor tissue. Larger controlled studies are needed to establish durable clinical benefit and an acceptable safety profile.
CAR-M is being investigated for several solid tumors, including TROP2-positive epithelial cancers, GPC3-positive liver cancer and HER2-expressing tumors. CREATE and Chinese investigator-led studies provide early clinical evidence. These programs have not established a broadly approved standard treatment, and efficacy claims must remain limited to reported trial findings. FDA authorization of MT-302 would require additional dose-escalation evidence and confirmatory clinical studies showing meaningful patient benefit.
In vivo CAR-M approaches deliver RNA or other genetic instructions that cause a patient’s own myeloid cells to express engineered receptors. CREATE uses targeted lipid nanoparticles in MT-302 and MT-303. This avoids some patient-specific ex vivo manufacturing but introduces questions about cell-selective delivery, repeat dosing and control of inflammatory activity.
CREATE Medicines is a verified active clinical developer, while Liberate Bio works on myeloid-targeted delivery and CellOrigin and Macera are linked to Chinese research. MaxCyte provides historical cell-engineering technology, and Carisma’s prior CAR-M programs are discontinued. Company inclusion does not imply an approved product or current treatment sales.
The main barriers are early clinical attrition, tumor heterogeneity, inflammatory toxicity, difficult GMP manufacturing and uncertain financing. The discontinuation of Carisma’s CT-0508 and CT-0525 programs illustrates attrition despite initial feasibility research. Regulatory authorities also require product identity, potency and controlled clinical evidence before any engineered macrophage therapy can be sold routinely.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.